Passage Bio Inc (PASG)
1.180
+0.03
(+2.60%)
USD |
NASDAQ |
Apr 22, 16:00
1.15
-0.03
(-2.53%)
After-Hours: 20:00
Passage Bio Cash from Financing (TTM): 0.135M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 0.135M |
September 30, 2023 | -0.499M |
June 30, 2023 | -0.907M |
March 31, 2023 | -1.402M |
December 31, 2022 | -1.353M |
September 30, 2022 | -0.31M |
June 30, 2022 | 0.142M |
March 31, 2022 | 1.071M |
December 31, 2021 | 166.66M |
Date | Value |
---|---|
September 30, 2021 | 166.60M |
June 30, 2021 | 166.60M |
March 31, 2021 | 164.48M |
December 31, 2020 | 228.75M |
September 30, 2020 | 227.55M |
June 30, 2020 | 337.45M |
March 31, 2020 | 385.35M |
December 31, 2019 | 175.60M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.402M
Minimum
Mar 2023
385.35M
Maximum
Mar 2020
118.58M
Average
164.48M
Median
Mar 2021
Cash from Financing (TTM) Benchmarks
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |
iBio Inc | 10.68M |
Theriva Biologics Inc | 0.625M |
Oragenics Inc | 0.2839M |